187 related articles for article (PubMed ID: 30532223)
1. Distillation of the clinical algorithm improves prognosis by multi-task deep learning in high-risk Neuroblastoma.
Maggio V; Chierici M; Jurman G; Furlanello C
PLoS One; 2018; 13(12):e0208924. PubMed ID: 30532223
[TBL] [Abstract][Full Text] [Related]
2. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
[TBL] [Abstract][Full Text] [Related]
3. Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.
Cornero A; Acquaviva M; Fardin P; Versteeg R; Schramm A; Eva A; Bosco MC; Blengio F; Barzaghi S; Varesio L
BMC Bioinformatics; 2012 Mar; 13 Suppl 4(Suppl 4):S13. PubMed ID: 22536959
[TBL] [Abstract][Full Text] [Related]
4. Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma.
Yu Y; Zeng Y; Xia X; Zhou JG; Cao F
Cancer Control; 2021; 28():10732748211033751. PubMed ID: 34569303
[TBL] [Abstract][Full Text] [Related]
5. Survival patterns of childhood neuroblastoma: an analysis of clinical data from Southern-Eastern European countries.
Karalexi MA; Servitzoglou M; Papadakis V; Kachanov D; Česen Mazič M; Baka M; Moschovi M; Kourti M; Polychronopoulou S; Stiakaki E; Hatzipantelis E; Dana H; Stefanaki K; Malama A; Themistocleous MS; Strantzia K; Shamanskaya T; Bouka P; Panagopoulou P; Kantzanou M; Ntzani E; Dessypris N; Petridou ET
Eur J Cancer Prev; 2023 May; 32(3):254-263. PubMed ID: 32925511
[TBL] [Abstract][Full Text] [Related]
6. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of gene expression-based classification for neuroblastoma.
Oberthuer A; Hero B; Berthold F; Juraeva D; Faldum A; Kahlert Y; Asgharzadeh S; Seeger R; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Vermeulen J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Weber A; Christiansen H; Grundy RG; Schardt K; Schwab M; Eils R; Warnat P; Kaderali L; Simon T; Decarolis B; Theissen J; Westermann F; Brors B; Fischer M
J Clin Oncol; 2010 Jul; 28(21):3506-15. PubMed ID: 20567016
[TBL] [Abstract][Full Text] [Related]
8. Predicting clinical outcomes in neuroblastoma with genomic data integration.
Baali I; Acar DAE; Aderinwale TW; HafezQorani S; Kazan H
Biol Direct; 2018 Sep; 13(1):20. PubMed ID: 30621745
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a 21-gene prognostic signature in neuroblastoma.
Gupta M; Kannappan S; Jain M; Douglass D; Shah R; Bose P; Narendran A
Sci Rep; 2023 Aug; 13(1):12526. PubMed ID: 37532697
[TBL] [Abstract][Full Text] [Related]
10. A three-gene expression signature model for risk stratification of patients with neuroblastoma.
Garcia I; Mayol G; Ríos J; Domenech G; Cheung NK; Oberthuer A; Fischer M; Maris JM; Brodeur GM; Hero B; Rodríguez E; Suñol M; Galvan P; de Torres C; Mora J; Lavarino C
Clin Cancer Res; 2012 Apr; 18(7):2012-23. PubMed ID: 22328561
[TBL] [Abstract][Full Text] [Related]
11. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
Rubie H; Delattre O; Hartmann O; Combaret V; Michon J; Bénard J; Peyroulet MC; Plantaz D; Coze C; Chastagner P; Baranzelli MC; Frappaz D; Lemerle J; Sommelet D
Eur J Cancer; 1997 Oct; 33(12):1917-22. PubMed ID: 9516824
[TBL] [Abstract][Full Text] [Related]
12. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
13. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
14. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.
Zhang W; Yu Y; Hertwig F; Thierry-Mieg J; Zhang W; Thierry-Mieg D; Wang J; Furlanello C; Devanarayan V; Cheng J; Deng Y; Hero B; Hong H; Jia M; Li L; Lin SM; Nikolsky Y; Oberthuer A; Qing T; Su Z; Volland R; Wang C; Wang MD; Ai J; Albanese D; Asgharzadeh S; Avigad S; Bao W; Bessarabova M; Brilliant MH; Brors B; Chierici M; Chu TM; Zhang J; Grundy RG; He MM; Hebbring S; Kaufman HL; Lababidi S; Lancashire LJ; Li Y; Lu XX; Luo H; Ma X; Ning B; Noguera R; Peifer M; Phan JH; Roels F; Rosswog C; Shao S; Shen J; Theissen J; Tonini GP; Vandesompele J; Wu PY; Xiao W; Xu J; Xu W; Xuan J; Yang Y; Ye Z; Dong Z; Zhang KK; Yin Y; Zhao C; Zheng Y; Wolfinger RD; Shi T; Malkas LH; Berthold F; Wang J; Tong W; Shi L; Peng Z; Fischer M
Genome Biol; 2015 Jun; 16(1):133. PubMed ID: 26109056
[TBL] [Abstract][Full Text] [Related]
15. [Occurrence and prognostic impact of selected factors in neuroblastoma in children].
Wieczorek A; Balwierz W
Przegl Lek; 2010; 67(6):393-8. PubMed ID: 21344768
[TBL] [Abstract][Full Text] [Related]
16. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
17. A deep neural network approach to predicting clinical outcomes of neuroblastoma patients.
Tranchevent LC; Azuaje F; Rajapakse JC
BMC Med Genomics; 2019 Dec; 12(Suppl 8):178. PubMed ID: 31856829
[TBL] [Abstract][Full Text] [Related]
18. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcomes among high-risk neuroblastoma patients receiving non-immunotherapy regimen: Multicenter study on behalf of the Thai Pediatric Oncology Group.
Suwannaying K; Monsereenusorn C; Rujkijyanont P; Techavichit P; Phuakpet K; Pongphitcha P; Chainansamit SO; Chotsampancharoen T; Winaichatsak A; Traivaree C; Sathitsamitphong L; Kanjanapongkul S; Komvilaisak P; Sanpakit K; Photia A; Seksarn P; Wiangnon S; Hongeng S;
Pediatr Blood Cancer; 2022 Sep; 69(9):e29757. PubMed ID: 35560972
[TBL] [Abstract][Full Text] [Related]
20. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
Yanik GA; Parisi MT; Naranjo A; Nadel H; Gelfand MJ; Park JR; Ladenstein RL; Poetschger U; Boubaker A; Valteau-Couanet D; Lambert B; Castellani MR; Bar-Sever Z; Oudoux A; Kaminska A; Kreissman SG; Shulkin BL; Matthay KK
J Nucl Med; 2018 Mar; 59(3):502-508. PubMed ID: 28887399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
